Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2022-01-06 Regulatory Filings
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
LYT-100 Shows Improved AE Profile vs Pirfenidone
Regulatory Filings Classification · 98% confidence The document is identified by the RNS Number header and the date format, indicating it is a regulatory announcement from a UK-listed company (PureTech Health PLC). The content details clinical trial results (LYT-100 study), plans for future development (initiating registration-enabling studies, dose-ranging study), and management changes (hiring SVP Clinical Development). This structure—announcing significant operational and clinical updates outside of a formal periodic report (like 10-K or IR)—is characteristic of a general regulatory news service release. Since it is not a formal Earnings Release (ER) which focuses only on financial highlights, nor a specific report like 10-K or IR, and it is not merely announcing the publication of another report (RPA), the most appropriate classification is the general regulatory filing category, RNS.
2022-01-06 English
Gelesis Adds to BOD & Declared Effective by SEC
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from PureTech Health PLC, dated January 5, 2022. The content primarily reports on an event concerning its Founded Entity, Gelesis: the appointment of a new director (Ali Bauerlein) and updates regarding Gelesis' upcoming NYSE listing via a business combination with Capstar SPAC. The text explicitly mentions the SEC declaring a Registration Statement effective and refers to a definitive proxy statement/prospectus being mailed to shareholders. While it discusses governance (board appointment) and capital structure (SPAC merger), the format is a press release distributed via RNS, announcing corporate developments rather than being the formal regulatory filing itself (like a 10-K, DEF 14A, or DVA). Since it is a general regulatory announcement that doesn't fit the highly specific categories like MANG (which focuses only on management *changes* without this broader context) or CAP (which focuses on financing activities), the most appropriate classification for a general, time-sensitive corporate update distributed via a regulatory wire is RNS.
2022-01-05 English
PDMR DEALING - PURCHASE OF SHARES
Director's Dealing Classification · 100% confidence The document is explicitly titled 'PDMR DEALING NOTIFICATION' and details a transaction ('Purchase of shares in market') made by a Director ('Bharatt Chowrira'). This directly corresponds to the definition of Director's Dealing, which is classified under the code DIRS. The presence of the RNS Number and the closing statement referencing RNS confirms it is a regulatory filing, but the specific content points overwhelmingly to DIRS.
2021-12-20 English
PRTC Provides Recap Ahead of Catalyst-Rich 2022
Management Reports Classification · 85% confidence The document is a corporate announcement titled 'PureTech Provides End of Year Report on Key Progress Across Wholly Owned Programs and Founded Entities'. It details operational, clinical, and strategic milestones for the company's pipeline and subsidiaries. While it contains substantive business information, it is not a formal financial statement (10-K or IR) nor a regulatory filing of a specific form. It functions as a management update on business progress and outlook, which aligns best with the Management Reports (MDA) category, as it provides a detailed explanation of business trends and operational developments. FY 2021
2021-12-16 English
PRTC Presents Data at ACNP Conference For LYT-300
Regulatory Filings Classification · 98% confidence The document is identified by the RNS Number header and contains a date (08 December 2021), indicating it is a regulatory or news announcement disseminated via the RNS system. The content describes the presentation of preclinical data for a drug candidate (LYT-300) at a scientific meeting (ACNP Annual Meeting) and provides updates on its Phase 1 clinical study. This is a typical announcement of scientific/clinical progress, which is generally classified as a general regulatory announcement or news release when distributed via RNS, especially since it is explicitly stated that 'Reach is a non-regulatory news service' and the announcement is identified as a Reach release. Since it is not a full financial report (10-K, IR), a specific earnings release (ER), or a formal proxy/voting document, the most appropriate general category for a non-regulatory news release distributed via RNS is 'Regulatory Filings' (RNS), as it serves as the fallback for miscellaneous announcements not covered by more specific codes like DIV, ER, or CAP. It is not an Investor Presentation (IP) as it is a press release format, not a slide deck.
2021-12-08 English
PRTC's Lymphatic Platform Candidate Human Study
Regulatory Filings Classification · 98% confidence The document begins with an RNS Number (7519U) and a date (07 December 2021), indicating it is a regulatory news service announcement. The content describes a specific corporate event: the initiation of a clinical study for a drug candidate (LYT-300) and provides detailed scientific and business updates. It is not a full Annual Report (10-K), an Earnings Release (ER), or a formal Audit Report (AR). It is a press release detailing operational and clinical progress, which often falls under general regulatory announcements or investor relations updates. Since it is a detailed announcement about clinical development and technology, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but given the format and RNS header, RNS is the most appropriate general category for non-standard, material announcements distributed via the regulatory wire. It is not a Report Publication Announcement (RPA) because it is the substantive news itself, not just an announcement that a report is available.
2021-12-07 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.